State legislatures and pharmacy boards build restrictions above the federal floor

State legislatures and professional licensing boards are writing their own rules for compounded GLP-1 drugs and peptides, layering requirements on top of federal law. An industry analysis published August 16, 2026 describes the result as a patchwork in which federal compliance alone no longer answers whether a given telehealth or compounding program is lawful in a particular state ^[1].

For most of the compounded semaglutide and tirzepatide boom, the main regulatory fight was federal: FDA shortage declarations, warning letters and enforcement discretion largely set the boundaries of what compounding pharmacies could make ^[1]. Under federal law, compounders may generally prepare copies of FDA-approved drugs when those drugs are on FDA's official shortage list, or under narrower exceptions tied to an individual patient's needs ^[1]. As FDA removed semaglutide and tirzepatide from its shortage lists over the past year, that federal pathway for mass compounding narrowed ^[1].

The analysis says states did not slow down in response — if anything, activity intensified, as legislatures and boards moved to fill perceived gaps in oversight of compounding pharmacies, telehealth prescribers and the wider peptide market, including products sold outside the GLP-1 category such as BPC-157 and other "research" peptides ^[1].

What states are actually doing

The specific mechanisms vary. States are using pharmacy licensing authority, pharmacy practice acts and consumer protection statutes to tighten when pharmacies may compound GLP-1 products, to scrutinize telehealth arrangements that connect out-of-state patients with compounded peptides, and to expand labeling and disclosure duties ^[1]. States are not preempted from going stricter than the federal baseline, and many are choosing to do so ^[1].

A separate law firm analysis published September 3, 2026 documents a wave of "Warning Notices" from state medical, nursing and pharmacy boards over recent weeks ^[2]. Most target "research use only" (RUO) peptides, but some are broader, describing peptides as "unapproved substances" and saying that administering them outside strict regulatory channels amounts to unprofessional conduct and malpractice ^[2]. Some warnings state that delegating to nurse practitioners or physician assistants does not relieve a physician's duty, and that patient waivers or disclaimers do not shift responsibility ^[2]. Boards have also targeted scope-of-practice violations where prescribers lacked state prescriptive authority or collaborative practice agreements; licenses have been suspended and practices have lost licenses ^[2].

Mississippi's warning is a joint statement from its boards of nursing, pharmacy and medicine ^[2]. South Carolina's says in part that "a licensed practitioner purchasing, distributing, or dispensing drugs or its components from an unpermitted facility is aiding and abetting unlicensed practices in violating state law involving drugs and may be disciplined for unprofessional conduct" ^[2]. A partial list of states that have issued warnings or are considered more restrictive includes Alabama, California, Connecticut, Louisiana, Mississippi, New Jersey, Ohio and South Carolina ^[2].

Some boards also require that prescription drugs, or components used in compounded drugs, be purchased only from entities licensed by that state's board of pharmacy ^[2]. FDA and consumer protection agencies have stepped up enforcement against deceptive marketing and increased seizures of imported peptides ^[2].

Notably, this state crackdown is running in the opposite direction from one federal move: an FDA advisory panel recommended adding six peptides to the 503A Bulks List so they could eventually be compounded ^[2]. The two sources agree the net effect is confusion for multi-state telehealth companies, which are pivoting as state telehealth rules diverge ^[1][2].

Why it matters for patients

The practical consequence is geographic. A pharmacy or telehealth company can offer an identical product and identical prescribing process and be compliant in one state and out of step in another ^[1]. That means availability, prescribing practices and the specific products offered may differ depending on where a patient lives ^[1].

It also means a program's federal status is not the whole picture. A company may point to FDA rules while a state board takes a different view of the same arrangement ^[1]. Board actions against prescribers — including suspensions and lost licenses — can disrupt continuity of care for people whose prescriber is affected ^[2].

Neither source quantifies how many patients are affected, how many states have acted in total, or which specific prescribing limits, telehealth exam standards or advertising rules each state has adopted. Those details are not yet known from this reporting.

What happens next

The analysis says to watch for more state legislative sessions taking up compounding and telehealth prescribing bills, further guidance and enforcement from state pharmacy boards, and any responsive action from FDA as it monitors the market after the shortage designations expired ^[1]. Legal challenges testing the limits of state authority are also considered plausible ^[1].